Potent clinical prognostic and systemic adjuvant therapeutic value of plasma fractalkine in PD-L1/PD-1 blockade immunotherapy for lung cancer
Ana Bocanegra, Gonzalo Fernández, Daniel Ajona, Hugo Arasanz, Ester Blanco, Miren Zuazo, Luisa Chocarro, Sergio Piñeiro-Hermida, Pilar Morente, Leticia Fernández, Maider Garnica, Ana Remirez, Maite Martinez-Aguillo, Idoia Morilla, Beatriz Tavira, Pablo Ramos, Miriam Echaide, Juan José Lasarte, Luis Montuenga, Ruth Vera, Ruben Pio, David Escors, Grazyna Kochan
doi: https://doi.org/10.1101/2022.06.16.22276511
Ana Bocanegra
1Oncoimmunology group, Navarrabiomed-Fundación Miguel Servet, Pamplona, Navarra, Spain
2IdISNA, Navarra Institute for Health Research, Pamplona, Spain
Gonzalo Fernández
3Medical Oncology Department, San Carlos Clinical Hospital, Madrid, Spain. IdISSC, San Carlos Clinical Hospital Institute for Health Research
Daniel Ajona
2IdISNA, Navarra Institute for Health Research, Pamplona, Spain
5Program in Solid Tumors, CIMA-University of Navarra, Pamplona, Spain
6CIBERONC, Centro de Investigación Biomédica en Red de Cáncer
7Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain
Hugo Arasanz
2IdISNA, Navarra Institute for Health Research, Pamplona, Spain
4Department of Oncology, University Hospital of Navarra, Pamplona, Navarra, Spain
Ester Blanco
1Oncoimmunology group, Navarrabiomed-Fundación Miguel Servet, Pamplona, Navarra, Spain
2IdISNA, Navarra Institute for Health Research, Pamplona, Spain
8Program in Gene Therapy and Regulation of Gene Expression, CIMA-University of Navarra, Pamplona, Spain
Miren Zuazo
1Oncoimmunology group, Navarrabiomed-Fundación Miguel Servet, Pamplona, Navarra, Spain
2IdISNA, Navarra Institute for Health Research, Pamplona, Spain
Luisa Chocarro
1Oncoimmunology group, Navarrabiomed-Fundación Miguel Servet, Pamplona, Navarra, Spain
2IdISNA, Navarra Institute for Health Research, Pamplona, Spain
Sergio Piñeiro-Hermida
1Oncoimmunology group, Navarrabiomed-Fundación Miguel Servet, Pamplona, Navarra, Spain
2IdISNA, Navarra Institute for Health Research, Pamplona, Spain
Pilar Morente
1Oncoimmunology group, Navarrabiomed-Fundación Miguel Servet, Pamplona, Navarra, Spain
2IdISNA, Navarra Institute for Health Research, Pamplona, Spain
Leticia Fernández
1Oncoimmunology group, Navarrabiomed-Fundación Miguel Servet, Pamplona, Navarra, Spain
2IdISNA, Navarra Institute for Health Research, Pamplona, Spain
Maider Garnica
1Oncoimmunology group, Navarrabiomed-Fundación Miguel Servet, Pamplona, Navarra, Spain
2IdISNA, Navarra Institute for Health Research, Pamplona, Spain
Ana Remirez
2IdISNA, Navarra Institute for Health Research, Pamplona, Spain
5Program in Solid Tumors, CIMA-University of Navarra, Pamplona, Spain
Maite Martinez-Aguillo
2IdISNA, Navarra Institute for Health Research, Pamplona, Spain
4Department of Oncology, University Hospital of Navarra, Pamplona, Navarra, Spain
Idoia Morilla
2IdISNA, Navarra Institute for Health Research, Pamplona, Spain
4Department of Oncology, University Hospital of Navarra, Pamplona, Navarra, Spain
Beatriz Tavira
2IdISNA, Navarra Institute for Health Research, Pamplona, Spain
5Program in Solid Tumors, CIMA-University of Navarra, Pamplona, Spain
9Cancer Center University of Navarra (CCUN), Pamplona, Spain
10Department of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, Pamplona, Spain
Pablo Ramos
1Oncoimmunology group, Navarrabiomed-Fundación Miguel Servet, Pamplona, Navarra, Spain
2IdISNA, Navarra Institute for Health Research, Pamplona, Spain
Miriam Echaide
1Oncoimmunology group, Navarrabiomed-Fundación Miguel Servet, Pamplona, Navarra, Spain
2IdISNA, Navarra Institute for Health Research, Pamplona, Spain
Juan José Lasarte
2IdISNA, Navarra Institute for Health Research, Pamplona, Spain
9Cancer Center University of Navarra (CCUN), Pamplona, Spain
11Program in Immunology and Immunotherapy, CIMA-University of Navarra, Pamplona, Spain
Luis Montuenga
2IdISNA, Navarra Institute for Health Research, Pamplona, Spain
5Program in Solid Tumors, CIMA-University of Navarra, Pamplona, Spain
6CIBERONC, Centro de Investigación Biomédica en Red de Cáncer
10Department of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, Pamplona, Spain
Ruth Vera
2IdISNA, Navarra Institute for Health Research, Pamplona, Spain
4Department of Oncology, University Hospital of Navarra, Pamplona, Navarra, Spain
Ruben Pio
2IdISNA, Navarra Institute for Health Research, Pamplona, Spain
5Program in Solid Tumors, CIMA-University of Navarra, Pamplona, Spain
6CIBERONC, Centro de Investigación Biomédica en Red de Cáncer
7Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain
David Escors
1Oncoimmunology group, Navarrabiomed-Fundación Miguel Servet, Pamplona, Navarra, Spain
2IdISNA, Navarra Institute for Health Research, Pamplona, Spain
Grazyna Kochan
1Oncoimmunology group, Navarrabiomed-Fundación Miguel Servet, Pamplona, Navarra, Spain
2IdISNA, Navarra Institute for Health Research, Pamplona, Spain
Article usage
Posted June 17, 2022.
Potent clinical prognostic and systemic adjuvant therapeutic value of plasma fractalkine in PD-L1/PD-1 blockade immunotherapy for lung cancer
Ana Bocanegra, Gonzalo Fernández, Daniel Ajona, Hugo Arasanz, Ester Blanco, Miren Zuazo, Luisa Chocarro, Sergio Piñeiro-Hermida, Pilar Morente, Leticia Fernández, Maider Garnica, Ana Remirez, Maite Martinez-Aguillo, Idoia Morilla, Beatriz Tavira, Pablo Ramos, Miriam Echaide, Juan José Lasarte, Luis Montuenga, Ruth Vera, Ruben Pio, David Escors, Grazyna Kochan
medRxiv 2022.06.16.22276511; doi: https://doi.org/10.1101/2022.06.16.22276511
Potent clinical prognostic and systemic adjuvant therapeutic value of plasma fractalkine in PD-L1/PD-1 blockade immunotherapy for lung cancer
Ana Bocanegra, Gonzalo Fernández, Daniel Ajona, Hugo Arasanz, Ester Blanco, Miren Zuazo, Luisa Chocarro, Sergio Piñeiro-Hermida, Pilar Morente, Leticia Fernández, Maider Garnica, Ana Remirez, Maite Martinez-Aguillo, Idoia Morilla, Beatriz Tavira, Pablo Ramos, Miriam Echaide, Juan José Lasarte, Luis Montuenga, Ruth Vera, Ruben Pio, David Escors, Grazyna Kochan
medRxiv 2022.06.16.22276511; doi: https://doi.org/10.1101/2022.06.16.22276511
Subject Area
Subject Areas
- Addiction Medicine (349)
- Allergy and Immunology (668)
- Allergy and Immunology (668)
- Anesthesia (181)
- Cardiovascular Medicine (2648)
- Dermatology (223)
- Emergency Medicine (399)
- Epidemiology (12228)
- Forensic Medicine (10)
- Gastroenterology (759)
- Genetic and Genomic Medicine (4103)
- Geriatric Medicine (387)
- Health Economics (680)
- Health Informatics (2657)
- Health Policy (1005)
- Hematology (363)
- HIV/AIDS (851)
- Medical Education (399)
- Medical Ethics (109)
- Nephrology (436)
- Neurology (3882)
- Nursing (209)
- Nutrition (577)
- Oncology (2030)
- Ophthalmology (585)
- Orthopedics (240)
- Otolaryngology (306)
- Pain Medicine (250)
- Palliative Medicine (75)
- Pathology (473)
- Pediatrics (1115)
- Primary Care Research (452)
- Public and Global Health (6527)
- Radiology and Imaging (1403)
- Respiratory Medicine (871)
- Rheumatology (409)
- Sports Medicine (342)
- Surgery (448)
- Toxicology (53)
- Transplantation (185)
- Urology (165)